Antares Pharma (ATRS) Misses Q3 EPS by 32c

Antares Pharma (NASDAQ: ATRS) reported Q3 EPS of ($0.32). Revenue for the quarter came in at $3.5 million.

For earnings history and earnings-related data on Antares Pharma (ATRS) click here.

You May Also Be Interested In

• Jefferies Starts Latigo Biotherapeutics (LTGO) at Buy
• Piper Sandler Upgrades Tempus AI Inc (TEM) to Overweight, 'On A Train Back To Upside, We're Not Jumping the Gun'
• Hyperscale Data holds 215 Bitcoin, sells 65 for $5.1M